lu ag13909
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 19, 2022 (NCT05669950)
Timeline
Indications
Mechanism of action
- Melanocortin receptor 2INHIBITOR
MC2R inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06471829 | Phase 2 | Jun 19, 2024 | Lundbeck |
| NCT05669950 | Phase 1 | Dec 19, 2022 | Lundbeck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lundbeck | For profit | 2 | 2 | 2 | 2022 |
1 organizations
Page 1 / 1